{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:42:57Z","timestamp":1792226577892,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pre-exposure prophylaxis (PrEP) is a significant public health intervention with proven efficacy and safety in the prevention of human immunodeficiency virus (HIV) infection, which has taken a considerable amount of time to reach Europe in relation to their transatlantic counterparts, namely, the United States of America (USA). There, it is perceived as being an essential prevention tool to be integrated within existing medical, behavioral and structural interventions in place for the management and containment of HIV infection in men who have sex with men (MSM). In a region such as Europe, with approximately double the USA population, it is estimated that not even 10% have proper access to PrEP, and given the lack of coordination with healthcare, taking PrEP has to be at their own expense. Here, we identify the reasons behind the 4-year lag in the approval of PrEP in the European Union\/European Economic Area (and Europe in general) and explore the efficacy and effectiveness of PrEP needed to be confirmed with some implementation or demonstration studies conducted in the region. Independent of the data gathered, access of MSM to PrEP is far from ideal in Europe and much still needs to be done. The demonstration of the cost-effectiveness of PrEP alongside other social and behavioral factors needs to be addressed, while the clear populations within MSM that will benefit from this intervention are properly identified and make use of the latest recommendations of the World Health Organization that consider not only daily PrEP but also event-driven PrEP. The momentum for the proper implementation of PrEP in the EU is not lost, and with the existence of generics and even new formulations, there is a renewed opportunity for unleashing the public health benefits arising from this pharmacological tool with other interventions in place (e.g., condoms, testing, and counseling).<\/jats:p>","DOI":"10.3389\/fmed.2021.722247","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T07:58:16Z","timestamp":1629878296000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe"],"prefix":"10.3389","volume":"8","author":[{"given":"Bruno","family":"Sepodes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eduardo","family":"Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Dr\u00e1fi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1056\/NEJMp1904113","article-title":"AIDS in America \u2014 back in the headlines at long last","volume":"380","author":"El-Sadr","year":"2019","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100943","DOI":"10.1016\/j.eclinm.2021.100943","volume":"35","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1916753","article-title":"Four decades of HIV\/AIDS \u2014 much accomplished, much to do","volume":"383","author":"Fauci","year":"2020","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/her\/cyr021","article-title":"The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches","volume":"26","author":"de","year":"2011","journal-title":"Health Educ Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.41.1900598","article-title":"Estimating the \u2018PrEP Gap': how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019","volume":"24","author":"Hayes","year":"2019","journal-title":"Euro Surveill."},{"key":"B7","unstructured":"UNAIDS Strategy 2016-2021: On the Fast-Track to End AIDS2015"},{"key":"B8","unstructured":"HIV Pre-Exposure Prophylaxis in the EU\/EEA and the UK: Implementation, Standards and Monitoring Operational Guidance2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/sextrans-2016-052699","article-title":"Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool","volume":"93","author":"Reyniers","year":"2016","journal-title":"Sex Transm Infect."},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e3182986f69","article-title":"Preexposure prophylaxis for HIV prevention: where have we been and where are we going?","volume-title":"J Acquir Immune Defic Syndr.","author":"Baeten","year":"2013"},{"key":"B11","unstructured":"Guidance on Oral Pre-Exposure Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex With Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects2012"},{"key":"B12","unstructured":"Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations2014"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","article-title":"Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature","volume":"21","author":"Koechlin","year":"2017","journal-title":"AIDS Behav."},{"key":"B14","unstructured":"Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV2015"},{"key":"B15","unstructured":"HIV\/AIDS Surveillance in Europe 20182019"},{"key":"B16","unstructured":"HIVAIDS Surveillance in Europe2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/COH.0000000000000223","article-title":"The European preexposure prophylaxis revolution","volume":"11","author":"Cairns","year":"2016","journal-title":"Curr Opin HIVAIDS."},{"key":"B18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1741-7015-11-186","article-title":"Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?","volume":"11","author":"Molina","year":"2013","journal-title":"BMC Med."},{"key":"B19","unstructured":"First Medicine for HIV Pre-Exposure Prophylaxis Recommended for Approval in the EU\n            EuropeanMedicines Agency\n          2016"},{"key":"B20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van","year":"2012","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","unstructured":"Regulatory Issues in Microbicide Development2010"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21103","DOI":"10.7448\/IAS.19.7.21103","article-title":"PrEP in Europe - expectations, opportunities and barriers","volume":"19","author":"McCormack","year":"2016","journal-title":"Int AIDS Soc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV preexposure prophylaxis: a review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA."},{"key":"B31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/COH.0000000000000170","article-title":"The current status of the use of oral medication to prevent HIV transmission","volume":"10","author":"Mayer","year":"2015","journal-title":"Curr Opin HIV AIDS."},{"key":"B32","unstructured":"Reflection Paper on the Non-Clinical and Clinical Development for Oral and Topical HIV Pre-Exposure Prophylaxis (PrEP)\n            EuropeanMedicines Agency\n          2012"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/ijsa.2011.051211","article-title":"The british HIV association\/british association for sexual health and hiv position statement on pre-exposure prophylaxis in the UK","volume":"23","year":"2012","journal-title":"Int J STD AIDS."},{"key":"B34","unstructured":"Truvada - European Public Assessment Report (EPAR) for Procedure No\n            EuropeanMedicines Agency\n          2016"},{"key":"B35","first-page":"359","article-title":"Awareness and knowledge of HIV pre-exposure prophylaxis among Australian gay and bisexual men: results of a national, online survey","volume-title":"Sex Health","author":"Holt","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s10461-016-1353-6","article-title":"Correlates of awareness of and willingness to use pre-exposure prophylaxis (PrEP) in gay, bisexual, and other men who have sex with men who use geosocial-networking smartphone applications in New York city","volume":"20","author":"Goedel","year":"2016","journal-title":"AIDS Behav."},{"key":"B37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-156-8-201204170-00001","article-title":"The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men","volume":"156","author":"Juusola","year":"2012","journal-title":"Ann Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/0956462415584490","article-title":"How many MSM in Europe could benefit from PrEP \u2013 a 9 billion Euro question?","volume":"26","author":"Kenyon","year":"2015","journal-title":"Int J STD AIDS."},{"key":"B39","unstructured":"No New Infections During Research on Preventive HIV Pill2018"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(19)30136-5","article-title":"Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study","volume-title":"Lancet HIV.","author":"Hoornenborg","year":"2019"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2352-3018(19)30341-8","article-title":"On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial","volume":"7","author":"Antoni","year":"2020","journal-title":"Lancet HIV."},{"key":"B42","unstructured":"What's the 2+1+1?2019"},{"key":"B43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/QAI.0000000000001579","article-title":"Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States syndromes","volume":"77","author":"Mayer","year":"2018","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/sextrans-2018-053705","article-title":"Use of, and likelihood of using, HIV pre-exposure prophylaxis among men who have sex with men in Europe and Central Asia: findings from a 2017 large geosocial networking application survey","volume":"95","author":"Bourne","year":"2019","journal-title":"Sex Transm Infect."},{"key":"B46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s13178-017-0278-9","article-title":"HIV pre-exposure prophylaxis (PrEP) is coming to Europe, but are gay men ready to accept it? Qualitative findings from Berlin, Germany","volume":"15","author":"Grov","year":"2017","journal-title":"Sex Res Soc Policy."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s10461-016-1379-9","article-title":"Awareness of pre-exposure prophylaxis for HIV, willingness to use it and potential barriers or facilitators to uptake among men who have sex with men in Spain","volume":"20","author":"Ferrer","year":"2016","journal-title":"AIDS Behav."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0204738","DOI":"10.1371\/journal.pone.0204738","article-title":"Awareness, knowledge, use, willingness to use and need of pre-exposure prophylaxis (PrEP) during world gay pride 2017","volume":"13","author":"Iniesta","year":"2018","journal-title":"PLoS ONE."},{"key":"B49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/09540121.2016.1259455","article-title":"Post-exposure prophylaxis awareness and use among men who have sex with men in London who use geosocial-networking smartphone applications","volume":"29","author":"Goedel","year":"2017","journal-title":"AIDS Care."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s10461-014-0760-9","article-title":"Use of geosocial networking (GSN) mobile phone applications to find men for sex by men who have sex with men (MSM) in Washington, DC","volume":"18","author":"Phillips","year":"2014","journal-title":"AIDS Behav."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e25105","DOI":"10.1002\/jia2.25105","article-title":"Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam","volume":"21","author":"Hoornenborg","year":"2018","journal-title":"J Int AIDS Soc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/S2468-2667(20)30186-9","article-title":"Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study","volume":"5","author":"Hanum","year":"2020","journal-title":"Lancet Public Health."},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hiv.12322","article-title":"Essentials from the 2015 European AIDS clinical society (EACS) guidelines for the treatment of adult HIV-positive persons","volume":"17","author":"Ryom","year":"2016","journal-title":"HIV Med."},{"key":"B54","unstructured":"The PrEP Situation in Europe\n            PrEPin Europe\n          2017"},{"key":"B55","unstructured":"How Do I Get PrEP?\n            PrEPin Europe\n          2017"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3018(19)30006-2","article-title":"For the greatest impact, end caps on PrEP access now","volume":"6","year":"2019","journal-title":"Lancet HIV."},{"key":"B57","unstructured":"PrEP and Sexually Transmitted Infections\n            PrEPin Europe\n          2019"},{"key":"B58","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12879-020-4831-4","article-title":"STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany","volume":"20","author":"Jansen","year":"2020","journal-title":"BMC Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drugpo.2019.03.021","article-title":"Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study","volume":"68","author":"Sewell","year":"2019","journal-title":"Int J Drug Policy."},{"key":"B60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10461-017-1873-8","article-title":"Rectal douching among men who have sex with men in paris: implications for HIV\/sti risk behaviors and rectal microbicide development","volume":"22","author":"Hambrick","year":"2018","journal-title":"AIDS Behav."},{"key":"B61","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10461-007-9301-0","article-title":"The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides","volume":"12","author":"Carballo-Dieguez","year":"2008","journal-title":"AIDS Behav."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1007\/s10461-018-2139-9","article-title":"Poppers and PrEP: use of pre-exposure prophylaxis among men who have sex with men who use inhaled nitrites","volume":"22","author":"Hambrick","year":"2018","journal-title":"AIDS Behav."},{"key":"B63","unstructured":"First Long-acting Injectable Antiretroviral Therapy for HIV Recommended for Approval\n            EuropeanMedicines agency\n          2020"},{"key":"B64","unstructured":"HPTN 083 Study Demonstrates Superiority of Cabotegravir for the Prevention of HIV2020"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/S2352-3018(16)30063-7","article-title":"The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring","volume":"3","author":"Hargreaves","year":"2016","journal-title":"Lancet HIV"},{"key":"B66","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.1016\/S2468-2667(21)00112-2","article-title":"HIV pre-exposure prophylaxis: scaling up for impact now and in the future","volume":"6","author":"Bavinton","year":"2021","journal-title":"Lancet Public Health."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.722247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T07:58:54Z","timestamp":1629878334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.722247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":66,"alternative-id":["10.3389\/fmed.2021.722247"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.722247","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"article-number":"722247"}}